Dabur India Ltd Result Update

Management Outlook & Key Priorities

• Management reiterated its guidance of delivering double-digit revenue growth for FY27, with H1 performance slightly ahead of its internal expectations.
• The company aims to sustain growth momentum across domestic FMCG and international businesses.
• Health & Wellness has been identified as a key strategic growth area, with a focus on scaling OTC and Digestives while reviving the Health Supplements portfolio.
• Premiumization will remain a key growth driver, with the premium portfolio contribution targeted to increase to 23% over the next 18 months.
• The company is accelerating its next three-year strategic planning exercise by approximately 18 months and expects to present its broader roadmap covering growth and portfolio evolution over the next 6–8 months.
• Management highlighted that specific business categories have the potential to deliver 20–50% growth, although it did not formally revise its overall growth guidance to 15–20%.
• Incremental advertising investments, distribution expansion and product innovation will remain key priorities.

Strategic M&A & New Growth Opportunities

• Strategic M&A remains an area where progress has been slower than initially anticipated.
• Management has rated its M&A progress as red under the existing strategic vision.
• The company remains interested in acquisitions that are strategically aligned, scalable, adjacent to existing categories and available at reasonable valuations.
• Dabur has approximately Rs. 6,000 crores of cash available in India, providing sufficient financial flexibility for potential acquisitions.
• However, management clarified that it will not pursue acquisitions merely to deploy surplus cash.
• The company is also developing its D2C capabilities through Dabur Shop and Science by Dabur, although these businesses remain relatively small.
• Integration of Sesa Care is expected to strengthen Dabur’s premium portfolio and provide additional growth opportunities.

Domestic FMCG Business

• India FMCG business recorded 10.7% growth during the quarter, with underlying volume growth of 5.5%.
• General Trade witnessed a significant recovery, delivering mid-to-high single-digit growth, supported by improved distribution and execution under Project Saksham.
• Premium brands continued to outperform regular brands, growing at approximately 4x the pace of the overall business.
• Premium portfolio contribution increased from 17% to 20% of domestic revenue over the last 18 months.
• Management is targeting an increase in premium portfolio contribution to 23% over the next 18 months.
• The company continues to focus on strengthening its core brands while expanding into adjacent categories and premium product segments.

Home & Personal Care (HPC) Business

• HPC business registered 10.9% growth during Q2FY27, supported by strong performances in hair care and home care.
• Shampoo and hair oil businesses delivered high double-digit growth, while the Home Care category also recorded double-digit growth.
• Skin and Salon business registered high single-digit growth, while Oral Care reported mid-single-digit growth.
• Management indicated that a substantial portion of the input-cost inflation was mitigated during the quarter through operational efficiencies and calibrated pricing.
• Focus remains on premiumisation, product innovation and strengthening distribution across key categories.

Healthcare Business

• Healthcare business grew 6.9% during the quarter, indicating a recovery, although management acknowledged that performance remains below its expectations.
• Digestives and OTC & Ethicals businesses continued to deliver strong double-digit growth.
• The broader healthcare portfolio, excluding the relatively weaker health supplements category, delivered growth in the teens.
• Management highlighted health and wellness as a key long-term growth opportunity, given Dabur’s established brand presence and capabilities.
• The company is focusing on reviving its health supplements portfolio while accelerating growth in the OTC and digestive categories.
• Chyawanprash remains a key area of focus, with initiatives around improved consumer communication, new formats and stronger winter-season execution.

Food & Beverages Business

• Food & Beverages business registered 17.4% growth during Q2FY27, supported by strong performance in Foods and a sequential recovery in Beverages.
• Foods business continued to deliver strong double-digit growth.
• Beverages witnessed an improvement on the back of favourable seasonality and premium product offerings.
• Premium offerings such as Real Active 100% juices, no-added-sugar juices and coconut water continued to gain traction.
• Management intends to drive growth through premiumisation, portfolio innovation and increasing penetration of health-oriented beverage products.

International Business

• International business delivered 20% growth in INR terms, supported by strong performances across Bangladesh, Egypt, Sub-Saharan Africa and Turkey.
• Growth remained broad-based across key international markets, reflecting improved business momentum.
• However, operating profitability was impacted by elevated supply-chain costs, freight and logistics expenses.
• Management continues to focus on strengthening market presence, improving product mix and driving operational efficiencies across international markets.

Distribution Strategy – Project Saksham

• Project Saksham has delivered significant improvements in the company’s General Trade distribution network.
• Distributor count has been reduced by approximately 43% through consolidation of previously separate distribution networks across HPC, Healthcare and Foods.
• Distributor attrition has declined by approximately 80%, while distributor throughput has doubled.
• Distributor return on investment has improved by around 30%.
• General Trade recorded mid-single-digit growth for the second consecutive quarter, with Q2FY27 registering its highest growth in approximately 19 quarters.
• The company clarified that distributor consolidation has not resulted in any geographical gaps or loss of market coverage.
• Management is also expanding its Retail Next programme across 40,000 stores, targeting growth of 1.5x the remaining General Trade network.
• Rural direct reach is being expanded to more than 100,000 geotagged villages.
• The chemist channel is another key focus area, particularly for expanding the reach of OTC and digestive products.

Premiumization, Advertising & Brand Investments

• Premium portfolio contribution has increased from 17% to 20% of revenue over the past 18 months.
• Premium brands are growing at approximately 4x the rate of the overall business and are margin accretive.
• Management aims to increase the premium portfolio contribution to 23% over the next 18 months.
• Digital media accounts for approximately 43% of total media expenditure, with influencer-led marketing increasing more than 3x.
• Under the Ignite strategy, the company plans to increase advertising and promotional investments by an additional 150–200 bps.
• Incremental investments will primarily be directed towards OTC, Digestives, Skin Care, Home Care and Foods categories.
• The company is increasingly leveraging AI for media planning and in-house content development to improve advertising effectiveness.